Chronic Infections: A Modern Epidemic

There is a category of patient that every experienced physician recognizes. They have seen multiple specialists. Their standard blood work is largely “normal.” They have been told their symptoms are stress-related, psychosomatic, or simply part of aging. They have fatigue that sleep does not resolve, cognitive difficulties that neurologists cannot explain, joint pain that rheumatologists find no inflammatory markers for, and a general sense that something is fundamentally wrong.

Many of these patients carry chronic infections.

This is not a fringe claim. It is an acknowledgment that our diagnostic framework — built primarily around acute infections with clear onset, identifiable pathogens, and definitive treatment — is poorly suited to the detection and management of persistent, low-grade, multisystemic infectious disease.

Why Chronic Infections Are Underdiagnosed

The problem begins with how we think about infection. Medical education teaches infection as a binary: you have an infection, or you do not. You treat it with an appropriate antibiotic, antiviral, or antifungal, and the infection resolves. This framework works well for acute pneumonia, urinary tract infections, and strep throat.

It works poorly for organisms that have evolved sophisticated survival strategies:

Intracellular persistence. Many pathogens — Borrelia, Bartonella, Mycoplasma, Chlamydia pneumoniae, Brucella — can survive inside human cells, shielded from both the immune system and many antibiotics. Standard serology may miss active infection because the immune response is compartmentalized [1].

Biofilm formation. Certain organisms form protective biofilm communities — structured aggregates encased in an extracellular matrix that conventional antibiotics penetrate poorly. I discuss biofilms in detail in a dedicated article, because understanding them is essential to understanding why infections persist.

Immune evasion. Chronic pathogens have evolved to modulate host immune responses. Borrelia burgdorferi changes its surface proteins. EBV establishes lifelong latency in B cells. These are not passive organisms hiding in corners — they actively manipulate the immune system to ensure their survival.

Diagnostic limitations. The standard tests for many chronic infections are insensitive. Two-tier Lyme testing misses an estimated 30-60% of cases, depending on the stage and population studied [2]. Bartonella testing has even lower sensitivity. EBV and CMV serology can show “past infection” even when reactivation is occurring. The result is that many chronically infected patients test “negative” by standard criteria.

The Scope of the Problem

Chronic infections are not rare. Consider the epidemiology:

• Lyme disease: The CDC acknowledges approximately 476,000 new cases annually in the United States alone. In Central Europe, where I practice, tick-borne diseases are endemic. An estimated 10-20% of treated Lyme patients develop persistent symptoms — a population numbering in the millions globally.

• Epstein-Barr virus (EBV): Approximately 95% of the global adult population is seropositive. In most people, EBV remains latent. In some, it reactivates, contributing to chronic fatigue, autoimmune disease, and potentially certain cancers [3].

• Post-COVID: An estimated 10-30% of COVID-19 survivors develop persistent symptoms. This represents tens of millions of people worldwide dealing with a post-infectious syndrome.

• Mycoplasma and Chlamydia pneumoniae: Common respiratory pathogens that can establish chronic, intracellular infection associated with fatigue, neurological symptoms, and respiratory complaints.

• Mold illness: While not a traditional “infection,” chronic mold exposure and Chronic Inflammatory Response Syndrome (CIRS) produce a clinical picture that overlaps significantly with chronic infection.

How Chronic Infections Cause Systemic Disease

The mistake that conventional medicine often makes is looking for the infection in the organ that hurts. A patient with joint pain gets a joint workup. A patient with cognitive complaints gets a neurological workup. A patient with fatigue gets a thyroid test.

Chronic infections do not respect organ boundaries. They cause systemic disease through several mechanisms:

Chronic immune activation. The persistent presence of microbial antigens keeps the immune system in a state of chronic activation, producing inflammatory cytokines (IL-1, IL-6, TNF-alpha) that affect every organ system. This is the mechanism behind much of the fatigue, cognitive dysfunction, and pain that chronic infection patients experience.

Molecular mimicry and autoimmunity. Some microbial antigens resemble human proteins. The immune response directed against the pathogen cross-reacts with the patient’s own tissues, producing autoimmune-like symptoms. This has been documented in Lyme disease (cross-reactivity with neural tissue) and streptococcal infection (rheumatic heart disease).

Mitochondrial disruption. Multiple chronic pathogens directly impair mitochondrial function, either through toxin production, intracellular parasitism, or the metabolic cost of sustained immune activation. This explains the profound fatigue that characterizes most chronic infectious conditions.

Endothelial damage. Chronic infections can damage blood vessel linings, impairing microcirculation. This is particularly relevant in post-COVID, where Dr. Beate Jaeger’s research on microclots and endothelial dysfunction has provided important insights into the mechanism of persistent symptoms.

Neuroinflammation. Many chronic pathogens — Borrelia, Bartonella, EBV, SARS-CoV-2 — can trigger neuroinflammation directly or indirectly, producing the cognitive symptoms (“brain fog”) that patients find so distressing.

A Physician’s Approach

After decades of treating complex infectious patients — first alongside my late father, Dr. Friedrich Douwes, who was a pioneer in integrative infectiology, and now leading these programs myself — I have developed an approach that differs from both conventional infectious disease practice and purely alternative medicine.

Diagnostic Thoroughness

I do not rely on a single test. My evaluation of a patient with suspected chronic infection includes:

• Comprehensive serological testing with awareness of test limitations
• Specialized testing where available (Elispot/LTT for cellular immune response, advanced PCR, dark-field microscopy)
• Assessment of co-infections — patients with one tick-borne infection frequently carry others (see co-infections overview)
• Evaluation of immune function — not just whether the immune system is fighting the infection, but how effectively
• Assessment of the terrain — mitochondrial function, nutritional status, hormonal balance, toxic burden. The infection exists within a host, and the host’s condition determines the trajectory.

Multimodal Treatment

In my clinical experience, chronic infections rarely respond to a single modality. The most effective treatment programs combine:

• Targeted antimicrobial therapy — antibiotics, antivirals, or antifungals selected based on identified pathogens and their susceptibility
• Biofilm disruption — because biofilm-encased organisms are resistant to antibiotics at standard concentrations
• Immune modulation — supporting the patient’s immune response rather than relying solely on antimicrobials
• Detoxification support — managing the inflammatory and toxic burden from both the infection and its treatment
• Herxheimer reaction management — the intensification of symptoms that can occur when pathogens are killed faster than the body can clear the debris (see Herxheimer article)
• Supportive care — nutritional optimization, mitochondrial support, sleep improvement, stress reduction

Honest Expectations

I want to be direct with patients and readers: chronic infections are treatable, but treatment is often prolonged, non-linear, and requires patience. Some patients achieve complete resolution. Others achieve significant improvement with some residual symptoms. A minority improve slowly or require ongoing management.

The factors that most influence outcome, in my experience:

1. Duration of illness before treatment (earlier is better)
2. Number and type of co-infections
3. Degree of immune compromise
4. The patient’s overall health, nutritional status, and capacity for self-care
5. Quality and comprehensiveness of the treatment program

What This Series Covers

The articles in this infectiology series address the conditions and concepts that matter most for patients dealing with chronic infectious disease:

• Lyme disease and why patients travel internationally for treatment
• Co-infections (Bartonella, Babesia, Ehrlichia, Mycoplasma, and others)
• Biofilms and persistence mechanisms
• Post-COVID syndrome, including the microclot hypothesis
• Reactivated viruses (EBV, CMV, HHV-6)
• Mold illness and CIRS
• Treatment considerations including Herxheimer reactions, antibiotic resistance, and apheresis

Each article presents the evidence honestly, distinguishes between what we know and what we are still learning, and reflects both published research and the clinical experience accumulated at our facility over decades.

References

1. Hodzic E, et al. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrobial Agents and Chemotherapy. 2008;52(5):1728-1736.
2. Marques AR. Laboratory diagnosis of Lyme disease: advances and challenges. Infectious Disease Clinics of North America. 2015;29(2):295-307.
3. Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301.

---

This content is educational and does not constitute medical advice. Chronic infections require comprehensive evaluation and treatment by a qualified physician experienced in complex infectious disease.